Stocksigma LogoStocksigma Logo

Morepen Laboratories Releases Monitoring Agency Report for Q2FY27 QIP Proceeds

CARE Ratings reported no material deviation in Morepen Laboratories' ₹200.00 crore QIP proceeds utilization for the quarter ended 30th Sep'26

Morepen Laboratories Releases Monitoring Agency Report for Q2FY27 QIP Proceeds

Morepen Laboratories Ltd · Others (Uncategorized) · 27 Oct 2026, 8:48 pm

Morepen Laboratories Releases Monitoring Agency Report for Q2FY27 QIP Proceeds CARE Ratings reported no material deviation in Morepen Laboratories' ₹200.00 crore QIP proceeds utilization for the quarter ended 30th Sep'26. Total net proceeds of ₹189.08 crore saw cumulative deployment of ₹181.10 crore, with ₹1.12 crore utilized in Q2FY27 for modernization and expansion of Baddi units. Working capital funding of ₹66.29 crore stands fully utilized. Unutilized proceeds of ₹7.98 crore remain invested in debt mutual funds and bank balances. Capex completion timelines were extended to 31st Mar'27, with the monitoring agency flagging potential cost overrun risks.

Original exchange filing (PDF)

More announcements from Morepen Laboratories Ltd

All Morepen Laboratories Ltd announcements